Top Markets
#1 EXOD EXOD +9.04%
#2 MarsCoin MarsCoin +9.00%
#3 Akedo Akedo +8.33%
#4 Solstice Solstice +8.24%
#5 peaq peaq +8.13%
#6 ETHGas ETHGas +7.27%
#7 龙虾 (Lobster) 龙虾 (Lobster) +6.51%
#8 Wrapped Flare Wrapped Flare +6.34%
#9 Official Trump Official Trump +6.27%
#10 Peapods Finance Peapods Finance +6.22%
Coin of the day
EXOD EXOD
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Intellia Therapeutics, Inc. Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLA
Classificação em ações #6842
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing... Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Preço da ação
$13.15
Última sincronização: 2026-08-27
Valor de mercado
$1.84B
Variação (1 dia)
-0.31%
Variação (1 ano)
13.35%
País
US
Negociar Intellia Therapeutics, Inc. (NTLA)

Categoria

Healthcare
Histórico de preços das ações de Intellia Therapeutics, Inc. (NTLA)
Preço de fecho mais alto: $12.36 em 2026-08-01

Preço de fecho mais baixo: $26.53 em 2016-05-01
Histórico de preços das ações da Intellia Therapeutics, Inc. de 2016 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 45.98%
2025 -30.41%
2024 -56.69%
2023 -19.53%
2022 -67.57%
2021 120.71%
2020 225.24%
2019 10.28%
2018 -24.22%
2017 26.96%
2016 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.36 39.87%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 50.29%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.16 -12.75%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $140.81 475.44%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.74%
CH